<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01703728</url>
  </required_header>
  <id_info>
    <org_study_id>000012</org_study_id>
    <nct_id>NCT01703728</nct_id>
  </id_info>
  <brief_title>Controlled Ovarian Stimulation by HP-hMG for IVF / ICSI Cycles: Study on Ovarian Hyper Stimulation Syndrome in a Cohort of Women From 18 to 36 Years Old.</brief_title>
  <acronym>SHOview</acronym>
  <official_title>SHOview Observational Study. Controlled Ovarian Stimulation by HP-hMG for IVF / ICSI Cycles: Study on Ovarian Hyper Stimulation Syndrome in a Cohort of Women From 18 to 36 Years Old.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ferring Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ovarian hyper stimulation syndrome (OHSS) is a potentially serious complication of ovarian&#xD;
      stimulation in IVF (In Vitro Fertilisation). The main objective of this study is to describe&#xD;
      the incidence of moderate or severe forms of OHSS in women between 18 and 36 years of age&#xD;
      treated with HP-hMG.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of moderate/severe OHSS</measure>
    <time_frame>2-12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of each form of OHSS: mild, moderate and severe</measure>
    <time_frame>2-13 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of moderate and of severe OHSS among patients treated by a GnRH agonist or antagonist desensitization protocol</measure>
    <time_frame>2-13 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OHSS clinical features description according to the Royal College of Obstetricians and Gynaecologists classification</measure>
    <time_frame>2-13 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients' baseline characteristics</measure>
    <time_frame>At baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dosage adjustment, modification of the treatment, coasting and cycle cancellation, no hCG administration and embryo transfer cancellation</measure>
    <time_frame>Up to 3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description and duration of hospitalisation, treatments prescribed</measure>
    <time_frame>2-13 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and reasons for stimulation arrest and no embryo transfer decision</measure>
    <time_frame>2-4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of oocytes retrieved, number of mature oocytes, fertilization rate, embryo quality, embryo freezing, number and quality of transferred embryos</measure>
    <time_frame>2-3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of serious and not serious adverse events</measure>
    <time_frame>2-13 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of patient's compliance to the prescribed treatment</measure>
    <time_frame>2-4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical pregnancy rate, spontaneous miscarriage and ongoing pregnancy rate</measure>
    <time_frame>4-13 weeks</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">455</enrollment>
  <condition>Ovarian Hyperstimulation Syndrome (OHSS)</condition>
  <arm_group>
    <arm_group_label>Highly purified menotropin (HP-hMG) treatment</arm_group_label>
    <description>Cohort of women from 18 to 36 years old treated by HP-hMG for controlled ovarian stimulation (COS) for a first or second cycle of IVF / ICSI.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Highly purified menotropin (HP- hMG) treatment</intervention_name>
    <description>No intervention: patients treated by highly purified menotropin for COS according to physicians' current practice</description>
    <arm_group_label>Highly purified menotropin (HP-hMG) treatment</arm_group_label>
  </intervention>
  <biospec_retention>None Retained</biospec_retention>
  <biospec_descr>
    <textblock>
      No biological samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Women from 18 to 36 years old treated by HP-hMG for controlled ovarian stimulation (COS)&#xD;
        for a first or second cycle of IVF / ICSI.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women who present infertility of more than one year and are candidates for a first or&#xD;
             second IVF cycle with or without ICSI for whom HP-hMG is prescribed for COS.&#xD;
&#xD;
          -  Absence of infertility treatment during the last 3 months before enrolment.&#xD;
&#xD;
          -  Age: from 18 to 36 years old.&#xD;
&#xD;
          -  BMI between 18 and 30 kg / m².&#xD;
&#xD;
          -  Presence of both ovaries accessible to puncture and absence of ovarian or uterine&#xD;
             abnormalities.&#xD;
&#xD;
          -  Male or female infertility.&#xD;
&#xD;
          -  Ovarian stimulation by HP-hMG with pituitary desensitization by a GnRH agonist or&#xD;
             antagonist.&#xD;
&#xD;
          -  Normal ovarian reserve according to physician habitual evaluation.&#xD;
&#xD;
          -  Consent to participate of the no-interventional study and signature of the patients'&#xD;
             information sheet.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of a chronic disease, cancer or endocrine disease that could potentially&#xD;
             influence the results of the stimulation or that represents a contraindication for&#xD;
             ovarian stimulation.&#xD;
&#xD;
          -  Known endometriosis grade III or IV.&#xD;
&#xD;
          -  Contraindication to the use of gonadotropins or current pregnancy diagnosed by the&#xD;
             clinician.&#xD;
&#xD;
          -  Recurrent miscarriages, known genetic disease of one of the partners or indication of&#xD;
             a preimplantation genetic diagnosis (PGD).&#xD;
&#xD;
          -  Smoking over than 10 cigarettes / day.´&#xD;
&#xD;
          -  Participation in an interventional study at the time of inclusion.&#xD;
&#xD;
          -  Known poor ovarian response in a previous cycle of stimulation (number of oocyte&#xD;
             collected ≤ 3, and / or more than 2 previous IVF/ICSI cycles and / or abnormal result&#xD;
             in ovarian reserve test (AMH &lt; 1 ng/ml with Immunotech equipment or AMH&lt;0.7 ng/ml with&#xD;
             DSL equipment).&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>36 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Development Support</last_name>
    <role>Study Director</role>
    <affiliation>Ferring Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cabinet Mirabeau Roy René (there may be other sites in this country)</name>
      <address>
        <city>Aix En Provence</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôtel Dieu</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique La Chataigneraie</name>
      <address>
        <city>Beaumont</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Léonard de Vinci</name>
      <address>
        <city>Chambray les tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHI</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Victor Jousselin</name>
      <address>
        <city>Dreux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Rhonalpin</name>
      <address>
        <city>Ecully</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet Médical Maréchal Leclerc</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier du Havre - Hôpital Jacques Monod</name>
      <address>
        <city>Le Havre</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet Médical Lille avenue de Dunkerque</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Jeanne de Flandre</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Privé Natecia</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Marseille -Hôpital Conception</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Maternité de Metz</name>
      <address>
        <city>Metz</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet Médical de Prony</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital St Vincent de Paul</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Mutualiste La Sagesse</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Barrière P, Dewailly D, Duhamel A, Gayet V. [Ovarian hyperstimulation syndrome after stimulation with highly purified hMGfor in vitro fertilization: Observational study SHOview]. Gynecol Obstet Fertil Senol. 2017 May;45(5):283-290. doi: 10.1016/j.gofs.2017.03.004. Epub 2017 Apr 29. French.</citation>
    <PMID>28461237</PMID>
  </results_reference>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>October 3, 2012</study_first_submitted>
  <study_first_submitted_qc>October 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2012</study_first_posted>
  <last_update_submitted>May 29, 2017</last_update_submitted>
  <last_update_submitted_qc>May 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Hyperstimulation Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Menotropins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

